238 related articles for article (PubMed ID: 31783291)
1. Tumor sidedness and efficacy of first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer: A network meta-analysis.
Wu CC; Wang JH; Lin PC; Liang CA; Huang CY; Lien HC; Chen CY; Chou KJ; Su YC
Crit Rev Oncol Hematol; 2020 Jan; 145():102823. PubMed ID: 31783291
[TBL] [Abstract][Full Text] [Related]
2. FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Pietrantonio F; Fucà G; Rossini D; Schmoll HJ; Bendell JC; Morano F; Antoniotti C; Corallo S; Borelli B; Raimondi A; Marmorino F; Niger M; Boccaccino A; Masi G; Lonardi S; Boni L; de Braud F; Di Bartolomeo M; Falcone A; Cremolini C
Oncologist; 2021 Apr; 26(4):302-309. PubMed ID: 33336844
[TBL] [Abstract][Full Text] [Related]
3. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies.
Boeckx N; Koukakis R; Op de Beeck K; Rolfo C; Van Camp G; Siena S; Tabernero J; Douillard JY; André T; Peeters M
Ann Oncol; 2017 Aug; 28(8):1862-1868. PubMed ID: 28449055
[TBL] [Abstract][Full Text] [Related]
4. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
Arnold D; Lueza B; Douillard JY; Peeters M; Lenz HJ; Venook A; Heinemann V; Van Cutsem E; Pignon JP; Tabernero J; Cervantes A; Ciardiello F
Ann Oncol; 2017 Aug; 28(8):1713-1729. PubMed ID: 28407110
[TBL] [Abstract][Full Text] [Related]
6. A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness.
Yoshino T; Hooda N; Younan D; Muro K; Shitara K; Heinemann V; O'neil BH; Herrero FR; Peeters M; Soeda J; Suh M; Reichert H; Mezzi K; Fryzek J; Chia V; Rehn M; Stintzing S
Eur J Cancer; 2024 May; 202():113975. PubMed ID: 38442645
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy With or Without Anti-EGFR Agents in Left- and Right-Sided Metastatic Colorectal Cancer: An Updated Meta-Analysis.
Wang ZX; Wu HX; He MM; Wang YN; Luo HY; Ding PR; Xie D; Chen G; Li YH; Wang F; Xu RH
J Natl Compr Canc Netw; 2019 Jul; 17(7):805-811. PubMed ID: 31319395
[TBL] [Abstract][Full Text] [Related]
8. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH
Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990
[TBL] [Abstract][Full Text] [Related]
9. Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab for Metastatic Colorectal Cancer.
Aljehani MA; Morgan JW; Guthrie LA; Jabo B; Ramadan M; Bahjri K; Lum SS; Selleck M; Reeves ME; Garberoglio C; Senthil M
JAMA Surg; 2018 Jan; 153(1):60-67. PubMed ID: 28975237
[TBL] [Abstract][Full Text] [Related]
10. Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials.
Rossini D; Boccaccino A; Carullo M; Antoniotti C; Dima G; Ciracì P; Marmorino F; Moretto R; Masi G; Cremolini C
Eur J Cancer; 2023 May; 184():106-116. PubMed ID: 36913832
[TBL] [Abstract][Full Text] [Related]
11. Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer.
Snyder M; Bottiglieri S; Almhanna K
Rev Recent Clin Trials; 2018; 13(2):139-149. PubMed ID: 29595113
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
13. Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum.
Ito T; Takashima A; Yamazaki K; Yukami H; Uetake H; Tsuda M; Suto T; Moriwaki T; Sugimoto N; Ojima H; Takii Y; Yasui H; Esaki T; Tsuji A; Goto M; Saruta M; Otsu S; Shinozaki K; Fujiwara T; Tamura T; Baba E; Shiozawa M; Denda T; Ueno H; Nagashima K; Shimada Y
Int J Clin Oncol; 2022 Sep; 27(9):1450-1458. PubMed ID: 35861943
[TBL] [Abstract][Full Text] [Related]
14. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.
Pietrantonio F; Petrelli F; Coinu A; Di Bartolomeo M; Borgonovo K; Maggi C; Cabiddu M; Iacovelli R; Bossi I; Lonati V; Ghilardi M; de Braud F; Barni S
Eur J Cancer; 2015 Mar; 51(5):587-94. PubMed ID: 25673558
[TBL] [Abstract][Full Text] [Related]
15. Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies.
Boeckx N; Koukakis R; Op de Beeck K; Rolfo C; Van Camp G; Siena S; Tabernero J; Douillard JY; André T; Peeters M
Clin Colorectal Cancer; 2018 Sep; 17(3):170-178.e3. PubMed ID: 29627309
[TBL] [Abstract][Full Text] [Related]
16. Long-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: Addition of Cetuximab to CAPOX/Bevacizumab in Metastatic Colorectal Cancer.
Ten Hoorn S; Mol L; Sommeijer DW; Nijman L; van den Bosch T; de Back TR; Ylstra B; van Dijk E; van Noesel CJM; Reinten RJ; Nagtegaal ID; Koopman M; Punt CJA; Vermeulen L
Clin Colorectal Cancer; 2023 Mar; 22(1):67-75. PubMed ID: 36564280
[TBL] [Abstract][Full Text] [Related]
17. Treatment outcome comparisons of first-line targeted therapy in patients with KRAS wild-type metastatic colorectal cancer: A nationwide database study.
Liang YH; Chen KH; Shao YY
Cancer Med; 2023 Jul; 12(14):15176-15186. PubMed ID: 37325970
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Regorafenib in Combination with Chemotherapy as Second-Line Treatment in Patients with Metastatic Colorectal Cancer: A Network Meta-Analysis and Systematic Literature Review.
Xie X; Zhang J; Hu H; Cai Y; Wu Z; Ling J; Li W; Deng Y
Adv Ther; 2020 Oct; 37(10):4233-4248. PubMed ID: 32770529
[TBL] [Abstract][Full Text] [Related]
19. First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
Zheng B; Wang X; Wei M; Wang Q; Li J; Bi L; Deng X; Wang Z
BMC Cancer; 2019 Mar; 19(1):280. PubMed ID: 30922269
[TBL] [Abstract][Full Text] [Related]
20. Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC).
Lawrence D; Maschio M; Leahy KJ; Yunger S; Easaw JC; Weinstein MC
J Med Econ; 2013 Dec; 16(12):1387-98. PubMed ID: 24102083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
